HEALTHSCIENTIFIC AMERICAN
America is embarking on a risky experiment with GLP-1s and aging
America is conducting a potentially risky experiment with GLP-1 receptor agonists, a class of weight-loss drugs, in the context of aging. The article explores uncertainties about long-term use of these drugs for older adults and their implications for health and longevity.
Related Signal
Adjacent reporting
- $1 drug hailed for its ability to slow aging has shocking unintended health consequences, new study suggests
- Meet the anti-aging ‘zombie cell’ compound longevity researchers are taking themselves
- STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
- The ‘longevity diet’ that can increase natural GLP-1 and reduce body fat: study
- Ozempic nation: America’s GLP-1 use nearly quadruples in just two years